Mehdorn E
Marienhospital Aachen.
Klin Monbl Augenheilkd. 1993 Sep;203(3):159-66. doi: 10.1055/s-2008-1045662.
The diagnosis of optic neuritis is based on clinical signs and symptoms. Ancillary testing is of little medical value, but helpful to evaluate the risk of developing multiple sclerosis and for proper counseling of the patient. The visual field defects caused by optic neuritis are less often central, but most often altitudinal or sectorial, and thus of little help to differentiate between papillitis and anterior ischemic optic neuropathy. In contrast to common belief, the usual therapy with oral prednisone at an initial dose of 100 mg/day may be harmful. This therapy does not accelerate recovery of visual function and does not lead to a better final result but increases the risk of new episodes of neuritis and may favour the development of multiple sclerosis. In the case of severe visual loss (visual acuity < or = 0.1) a megadose-therapy with 1000 mg methylprednisolone/day accelerates the recovery of visual function. Side effects of the megadose therapy are infrequent and not severe. In the case of moderate visual loss (visual acuity > or = 0.5) no therapy is advocated.
视神经炎的诊断基于临床体征和症状。辅助检查的医学价值不大,但有助于评估发生多发性硬化的风险以及对患者进行适当的咨询。视神经炎所致的视野缺损较少为中心性的,而多为象限性或扇形的,因此对视乳头炎和前部缺血性视神经病变的鉴别帮助不大。与普遍看法相反,初始剂量为100mg/天的口服泼尼松常规治疗可能有害。这种治疗不会加速视觉功能的恢复,也不会带来更好的最终结果,反而会增加神经炎新发作的风险,并可能促进多发性硬化的发展。在严重视力丧失(视力≤0.1)的情况下,1000mg/天的甲泼尼龙大剂量疗法可加速视觉功能的恢复。大剂量疗法的副作用少见且不严重。在中度视力丧失(视力≥0.5)的情况下,不主张进行治疗。